Gilead Credit Agreement

On September 13, 2020, Gilead and Immunomedics announced that Gilead, Immunomedics and Maui Merger Sub, Inc., a subsidiary of Gilead (“Purchaser”), a wholly owned subsidiary of Gilead, have signed a definitive merger agreement under which a takeover bid is filed. In accordance with the merger agreement, Gilead and The Buyer launched on September 24, 2020 an offer to repurchase all outstanding shares of Immunomedics at a price of $88.00 per share, net to the seller in cash, excluding interest. On October 23, 2020, Gilead successfully completed the offer of all unpaid common shares of Immunomedics and accepted all outstanding and unreased shares upon the expiry of the offer, And Gilead will immediately pay for these shares, which represent approximately 81.38% of the outstanding shares of Immunomedics (not including 12,451,797 shares provided by guaranteed delivery communications, or about 5.38% of the outstanding shares). In accordance with the terms of the merger treaty, the purchaser merged with and towards Immunomedics on October 23, 2020. All outstanding common shares of Immunomedics, with the exception of (i) Gilead shares, Purchaser or one of Gilead`s direct or indirect subsidiaries, (ii) the shares of Immunomedics (or in the treasury of Immunomedics) and (iii) the shares of Immunomedics shareholders, which require due action to be valued in accordance with Delaware law, have been cancelled and converted into the right to receive $88.00 per share. Gilead Sciences, Inc. is a research-based biopharmaceutical company that detects, develops and markets innovative medicines in areas where there are marginal and medical medical needs. The company strives to transform and simplify the care of people with life-threatening diseases around the world. Gilead operates in more than 35 countries around the world and is headquartered in Foster City, California. For more information about Gilead Sciences, please visit the company`s website at www.gilead.com. Gilead Sciences – September 8, 2017, co entered into a credit agreement for a $6.0 billion credit facility – SEC Filing The agreement consists of three priority unsecured credit facilities: US$1 billion due 364 days after the deadline, US$2.5 billion maturing three years after closing and US$2.5 billion maturing five years after the closing date.

Gilead Sciences – The proceeds from loans under a credit agreement are used to finance part of the acquisition of Kite Pharma, Inc. Source Code: [bit.ly/2eWmxvK] Other corporate hedge: the proceeds of the credit contract are used to finance part of Kite Pharma Inc.`s $11.9 billion acquisition. In the third quarter of 2020, Gilead has also entered into several additional agreements to advance its emerging and complementary oncology portfolio: for more information about Gilead Sciences, please visit the company`s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. For more information about Gilead Sciences, Inc. please visit www.gilead.com or call Gilead`s Department of Public Affairs at 1-800-GILEAD-5 (1-800-445-3235).

Comments are closed.